The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment

Journal of Thrombosis and Thrombolysis

Volumn 11, Issue 2, 2001, Pages 143-149

  Walenga, Jeanine M ^a   Hoppensteadt, Debra ^a   Pifarré, Roque ^a   Fox, Norma Lynn ^b   Forman, Sandra ^c   Hunninghake, Donald B ^d   Campeau, Lucien ^e   Herd, J Alan ^f   Hoogwerf, Byron J ^g   Hickey, Ann ^h   Probstfield, Jeffrey L ⁱ   Terrin, Michael L ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e MONTREAL HEART INSTITUTE   (Canada)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anticoagulants; Coronary artery bypass; Hemostasis; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 7; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; GRAFT OCCLUSION; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; INTERNATIONAL STANDARD UNIT; MALE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; TITRIMETRY;

ADULT; AGED; ANTICOAGULANTS; ASPIRIN; CORONARY ARTERY BYPASS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FACTOR VII; FEMALE; FIBRINOGEN; GRAFT OCCLUSION, VASCULAR; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PROTHROMBIN; RECURRENCE; SAPHENOUS VEIN; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VON WILLEBRAND FACTOR; WARFARIN;

EID: 0034916087     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011276700426     Document Type: Article

References (30)

1. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
2. Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery
3. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors
4. Antithrombotic therapy in cardiovascular disease
5. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement
6. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery: A prospective, randomized study
7. Oral anticoagulation in the prevention of one-year vein graft occlusion after aortocoronary bypass surgery: Optimal therapeutic range and practical limitations
8. Fixed minidose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery
9. Reduction of factor VII coagulant activity (VIIC) a risk factor for ischemic heart disease by fixed dose warfarin: A double blind crossover study
10. Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose
11. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy
12. The hemostatic effects of 1 mg daily warfarin on post CABG patients
13. Multivariate regression analysis for categorical data
14. Long term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial
15. Prevention of venous thrombosis with minidose warfarin after joint replacement
16. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement
17. Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery despite inhibiting the post operative rise in plasminogen activator inhibitor activity
18. The pathophysiology of the prethrombotic state in humans: Insight gained from studies using markers of hemostatic system activation
19. Monitoring "mini-intensity" anticoagulation with warfarin: Comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1 + 2 levels
20. Changes of prothrombin fragment 1 + 2 (F 1 + 2) as a function of increasing intensity of oral anticoagulation. Considerations on the suitability of F 1 + 2 to monitor oral anticoagulant treatment
21. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
22. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial
23. Oral anticoagulants. Mechanisms of action, clinical effectiveness, and optimal therapeutic range
24. Thrombosis prevention trial: Randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk
25. Factor VIII, von Willebrand factor and the risk of major ischemic heart disease in the Caerphilly Study
26. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischemic heart disease in the Caerphilly Study
27. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
28. Coagulation factor VII and the risk of coronary heart disease in healthy men
29. Suppression of plasma-activated factor VII levels by warfarin therapy